{
    "root": "107bfafe-85ec-464b-b219-4c88679f2281",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250228",
    "ingredients": [
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROXYPROPYLCELLULOSE",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM CARBONATE DECAHYDRATE",
            "code": "LS505BG22I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "pantoprazole proton pump inhibitor ( ppi ) indicated following : short-term treatment erosive esophagitis associated gastroesophageal reflux disease ( gerd ) ( 1.1 ) maintenance healing erosive esophagitis ( 1.2 ) pathological hypersecretory conditions including zollinger-ellison ( ze ) syndrome ( 1.3 )",
    "contraindications": "indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 wks children ( 5 years older ) \u2265 15 kg < 40 kg 20 mg daily 8 wks \u2265 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily * pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily * controlled extend beyond 12 months full prescribing information instructions",
    "warningsAndPrecautions": "product : 50090-1100 ndc : 50090-1100-0 30 tablet , delayed release bottle ndc : 50090-1100-1 90 tablet , delayed release bottle",
    "adverseReactions": "pantoprazole sodium contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) \u00a0Syndrome ( 1.3 )",
    "contraindications_original": "Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) \u2265 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks \u2265 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily * Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions",
    "warningsAndPrecautions_original": "Product:    50090-1100\n                  NDC:    50090-1100-0   30 TABLET, DELAYED RELEASE in a BOTTLE\n                  NDC:    50090-1100-1   90 TABLET, DELAYED RELEASE in a BOTTLE",
    "adverseReactions_original": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6)].\n                  \n                  \n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}